Perindopril
As of the edition of 20 October 2026, Perindopril is a small molecule: marketed, first approved in 1988 (FR); acts on ACE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Small molecule
- Brand name
- Aceon
- First approved
- 22 June 1988 (FR)
- Approvals on record
- 18 in 5 regions
- Holder of the most recent approval
- Servier; 5 holders in all
- Registered trials
- 39, 5 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones; Cancer; Digestive system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Perindopril.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACE | Angiotensin-converting enzyme | P12821 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 8 | 1 | 0 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 6 | 3 | 0 | 2 |
| Phase 3 | 6 | 3 | 0 | 2 |
| Phase 4 | 14 | 7 | 0 | 1 |
| All trials | 39 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| BMG Pharma | Earlier holder | 1993 to now |
| Servier | Applicant and Lead sponsor of trials | 1994 to now |
| Symplmed Pharmaceuticals | Acquired holder | 2014 to now |